OISASCRS

Alice Epitropoulos, MD, on How Xiidra, TrueTear, and Other Treatments Impact Practices, Patients

Ophthalmology Innovation Podca

9 years ago

Alice Epitropoulos, MD, on How Xiidra, TrueTear, and Other Treatments Impact Practices, Patients

oisascrs

ois

ophthalmology

investing

venture capital

+5

+4

+3

+3

+3

+2

+2

+1

11:33

oisascrs

ois

ophthalmology

investing

venture capital

+5

+4

+3

+3

+3

+2

+2

+1

CEO Ram Rao Discusses Juvene, the Rise of Presbyopia, and How LensGen Raised $21 million

Ophthalmology Innovation Podca

9 years ago

CEO Ram Rao Discusses Juvene, the Rise of Presbyopia, and How LensGen Raised $21 million

oisascrs

ois

ophthalmology

investing

venture capital

+5

+4

+3

+3

+3

+2

+2

+1

11:41

oisascrs

ois

ophthalmology

investing

venture capital

+5

+4

+3

+3

+3

+2

+2

+1

Alcon's Attias Touts Growing Pipeline Including Progress in Glaucoma and Google Projects

Ophthalmology Innovation Podca

9 years ago

Alcon's Attias Touts Growing Pipeline Including Progress in Glaucoma and Google Projects

oisascrs

ois

ophthalmology

investing

venture capital

+5

+4

+3

+3

+3

+2

+2

+1

11:09

oisascrs

ois

ophthalmology

investing

venture capital

+5

+4

+3

+3

+3

+2

+2

+1

Can OIS Help Make Myopia Great Again? Co-chair Kliman Discusses Inventive New Panel, Opportunities

Ophthalmology Innovation Podca

9 years ago

Can OIS Help Make Myopia Great Again? Co-chair Kliman Discusses Inventive New Panel, Opportunities

oisascrs

ois

ophthalmology

investing

venture capital

+5

+4

+3

+3

+3

+2

+2

+1

09:46

oisascrs

ois

ophthalmology

investing

venture capital

+5

+4

+3

+3

+3

+2

+2

+1

CEO Brent Saunders Lays out Allergan’s Plans for Ophthalmology, Restasis, and Innovation

Ophthalmology Innovation Podca

8 years ago

CEO Brent Saunders Lays out Allergan’s Plans for Ophthalmology, Restasis, and Innovation

oisascrs

ois

ophthalmology

investing

venture capital

+5

+4

+3

+3

+3

+2

+2

+1

09:51

oisascrs

ois

ophthalmology

investing

venture capital

+5

+4

+3

+3

+3

+2

+2

+1

What Does TearScience Deal Mean for J&J? Group Chair Ashley McEvoy Shines Light on Future Plans

Ophthalmology Innovation Podca

9 years ago

What Does TearScience Deal Mean for J&J? Group Chair Ashley McEvoy Shines Light on Future Plans

oisascrs

ois

ophthalmology

investing

venture capital

+5

+4

+3

+3

+3

+2

+2

+1

12:04

oisascrs

ois

ophthalmology

investing

venture capital

+5

+4

+3

+3

+3

+2

+2

+1

CEO Ludwin Monz Discusses Zeiss’ “Important” Management Hires, SMILE, and the Future of Diagnostics

Ophthalmology Innovation Podca

9 years ago

CEO Ludwin Monz Discusses Zeiss’ “Important” Management Hires, SMILE, and the Future of Diagnostics

oisascrs

ois

ophthalmology

investing

venture capital

+5

+4

+3

+3

+3

+2

+2

+1

10:41

oisascrs

ois

ophthalmology

investing

venture capital

+5

+4

+3

+3

+3

+2

+2

+1

Hear Details on Feb. 28 Dry Eye Dinner at SECO, Interview with J&J's Dry Eye Head, Joe Boorady

Ophthalmology Innovation Podca

8 years ago

Hear Details on Feb. 28 Dry Eye Dinner at SECO, Interview with J&J's Dry Eye Head, Joe Boorady

oisascrs

oisaao

oisasrs

kol

healthcare

+5

+4

+3

+3

+2

+1

12:38

oisascrs

oisaao

oisasrs

kol

healthcare

+5

+4

+3

+3

+2

+1

NEA's Behbahani, with New Fund to Invest, Discusses VC's Strong Interest in Ophthalmology

Ophthalmology Innovation Podca

9 years ago

NEA's Behbahani, with New Fund to Invest, Discusses VC's Strong Interest in Ophthalmology

oisascrs

ois

ophthalmology

investing

venture capital

+5

+4

+3

+3

+3

+2

+2

+1

13:05

oisascrs

ois

ophthalmology

investing

venture capital

+5

+4

+3

+3

+3

+2

+2

+1

Donnenfeld Discusses How New Diagnostics, Treatments Impact His Practice and Patients

Ophthalmology Innovation Podca

9 years ago

Donnenfeld Discusses How New Diagnostics, Treatments Impact His Practice and Patients

oisascrs

ois

ophthalmology

investing

venture capital

+5

+4

+3

+3

+3

+2

+2

+1

09:21

oisascrs

ois

ophthalmology

investing

venture capital

+5

+4

+3

+3

+3

+2

+2

+1